Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 589.88% | 588.40% | 536.44% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 589.88% | 588.40% | 536.44% | -- | -- |
| Cost of Revenue | 20.52% | -112.40% | -156.04% | -- | -- |
| Gross Profit | 210.75% | 298.95% | 340.29% | -- | -- |
| SG&A Expenses | 19.90% | 16.92% | 15.41% | 5.49% | -8.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.94% | 9.91% | 3.75% | -8.20% | -16.61% |
| Operating Income | 29.61% | 31.76% | 15.07% | 21.05% | 24.63% |
| Income Before Tax | 39.84% | 6.87% | 14.21% | 23.47% | 23.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.84% | 6.87% | 14.21% | 23.47% | 23.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.84% | 6.87% | 14.21% | 23.47% | 23.77% |
| EBIT | 29.61% | 31.76% | 15.07% | 21.05% | 24.63% |
| EBITDA | 30.28% | 32.43% | 15.24% | 21.40% | 24.90% |
| EPS Basic | 46.24% | 44.28% | 58.46% | 64.29% | 51.19% |
| Normalized Basic EPS | 44.86% | 43.21% | 57.75% | 63.81% | 52.42% |
| EPS Diluted | 46.24% | 44.28% | 58.46% | 64.29% | 51.27% |
| Normalized Diluted EPS | 44.86% | 43.21% | 57.75% | 63.81% | 52.42% |
| Average Basic Shares Outstanding | 65.03% | 49.20% | 100.61% | 123.42% | 81.85% |
| Average Diluted Shares Outstanding | 65.03% | 49.20% | 100.61% | 123.42% | 81.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |